LONDON - Three former Shire Pharmaceuticals Group plc executives have raised $7.1 million to acquire nasal drug delivery technology from West Pharmaceutical Services Inc. (WPS), along with $40 million for product development, as the foundation of a new company, Archimedes Pharma Ltd. (BioWorld International)

Like Many Others, Scotland Wants Piece Of Biotech Pie

Feb. 16, 2005

By Nuala Moran

UK Report Suggests Changes For Better Access To Capital

Feb. 16, 2005

By Nuala Moran

Archimedes Pharma Started As Nasal Drug Delivery Firm

Feb. 16, 2005

By Nuala Moran

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
mRNA flu vaccine can activate broad germinal center response
BioWorld
On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...